AGA. V. Goryunov

A. V. Goryunov

*This is an algorithmically generated author record based on publicly available information.

A. V. Goryunov has a total of 61 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Increased nervous excitability, anxiety, and sleep disorders in childhood — the role of multicomponent low-dose medications

    by A.V. Goryunov, N.I. Pavliv, O.V. Shushpanova, T.E. Blinova, N.I. Golubeva

    Anxiety, emotional excitability, and sleep disturbances are common in pediatric populations, often emerging during stressful periods such as chronic family conflict, parental divorce, initial socialization in kindergarten, and the beginning of formal schooling. These conditions are frequently linked to autonomic nervous system (ANS) dysfunction. During such periods, nervous system instability impairs stress adaptation and may lead to neurotic reactions. Chronic stress and anxiety can trigger neuroinflammatory processes, which further intensify anxiety and ANS dysfunction. Clinically, these mechanisms present as autonomic disorders, including various types of pain, sleep disturbances, increased anxiety, emotional instability, and behavioral disorders. Higher rates of anxiety and insomnia are observed in children with attention deficit hyperactivity disorder, autism spectrum disorders, and other psychiatric conditions. Early intervention that combines psychological correction with safe pharmacotherapy is critical. Given the limitations of psychopharmacological treatments in pediatric patients, standardized phytotherapy is commonly employed, particularly low-dose, multicomponent medications such as Nervoheel and Neurexan. A review of current studies suggests that Neurexan and Nervoheel are effective in managing neurotic anxiety, fears, and sleep disorders in children, and may also improve ANS dysfunction associated with emotional instability, irritability, fatigue, and senestalgia.

  • Russian early childhood psychiatry: challenges and prospects

    by A.V. Goryunova, Yu.S. Shevchenko, A.V. Goryunov

    This article examines the main challenges In Russian early childhood psychiatry. It outlines the developmental stages of Russian “micropsychiatry,” which addresses children from the first year of life to age four, and notes its close relationship with pediatrics, neurology, and early childhood psychology. The increasing prevalence of mental disorders among children and adolescents in recent decades underscores the need for early diagnosis, rehabilitation, comprehensive treatment, and prevention within national policies aimed at strengthening the mental health of the younger generation. Establishing a system for early detection and comprehensive intervention for developmental disorders in children within primary healthcare settings has therefore become a priority. Early childhood psychiatry currently faces clinical-diagnostic, classification, terminological, interdepartmental, therapeutic-corrective, and organizational-methodological challenges, which this article examines along with proposed solutions.

  • Obsessive-compulsive disorder in the context of schizotypal disorder among children and adolescents

    by T.E. Blinova, Yu.A. Chaika, A.V. Goryunov

    This review analyzes obsessive-compulsive disorder (OCD) in the context of schizotypal disorder (STD) among children and adolescents. Recent studies indicate that children with schizophrenia spectrum disorders have an elevated risk of developing obsessive-compulsive symptoms. Additionally, comorbidity of OCD with schizophrenia or STD is linked to a more severe clinical trajectory and lower responsiveness to treatment. The manifestation of OCD in patients with STD diverges from classical presentations, requiring comprehensive diagnostic approaches to elucidate etiological mechanisms, assess prognosis, and guide effective interventions. The literature emphasizes both the importance and the ongoing underdevelopment of this area. This issue lies at the intersection of two principal challenges in contemporary psychiatry: the nosological distinction between obsessive-compulsive and schizophrenia spectrum disorders, and the development of precise diagnostic and therapeutic strategies within the psychotic disorder continuum. To date, no studies have examined correlations between STD and OCD symptoms using validated psychometric tools, such as the Children’s Yale—Brown Obsessive—Compulsive Scale (CY-BOCS) and the Schizotypal Personality Questionnaire (SPQ). Evidence of the adverse effects of comorbid symptoms on social functioning and prognosis further highlights the clinical relevance of this topic for improving quality of life in these patients.

  • Expert Council resolution: adjunctive pharmacotherapy for hyperkinetic disorders (attention deficit hyperactivity disorder) in children and adolescents

    by O.L. Lapochkin, V.P. Zykov, N.N. Zavadenko, A.V. Goryunov, L.S. Chutko, A.N. Barhatova, E.V. Koren, T.A. Kupriyanova, A.P. Skoromets, S.V. Grechany, et al.

    On July 16, 2026, the Expert Council of the National Association of Pediatric Neurologists convened in Moscow in a hybrid format. The Council reviewed adjunctive pharmacotherapy for hyperkinetic disorders (F90 according to ICD-10; Attention-deficit hyperactivity disorders, ADHD; 6A05 according to ICD-11) in children and adolescents, focusing on evidence and clinical experience with medications used In Russian practice beyond the international first-line standard. Using the 2019 CECCMP evidence evaluation system and the current procedure for developing clinical guidelines linked to ICD-10 categories in the Russian Federation, the Council stratified medications into two groups. Group A, with the strongest evidence base (double-blind randomized controlled trial with a primary endpoint achieved in ADHD), includes Prospekta. Group B, with a limited evidence base, includes Cortexin, Tenoten for children, Cerebrolysin, Semax, Cogitum, Magne B6, Pantoham, and Mexidol. Adjunctive pharmacotherapy is recommended only as part of a multidisciplinary approach that includes psychoeducation and behavioral interventions. It is not a substitute for atomoxetine therapy for eligible patients.

  • Pediatric clinical and psychopathological aspects of anti-NMDA receptor and glutamate decarboxylase autoimmune encephalitis

    by A.V. Abramov, A.V. Goryunov, Yu.A. Chaika

    Autoimmune encephalitides (AE) are a diverse group of diseases characterized by different etiological and clinical features, with pathogenesis involving immunological damage to the brain’s protein structures. Diagnosing patients with AE who present with mental disorders poses significant challenges. Epidemiological data show an increasing prevalence of AE. In certain subtypes of AE, especially those that manifest during childhood, there are reports of initial presentations that consist solely of psychopathological symptoms. This review summarizes the current state of knowledge regarding AE in children, outlines diagnostic criteria and psychopathological features based on both international and Russian literature.

  • Consensus of the International Interdisciplinary Expert Council on the treatment of comorbidities in pediatric ADHD

    by V.P. Zykov, M.V. Barkhatov, O.V. Bykova, N.A. Geppe, A.V. Goryunov, A.V. Goryunova, N.A. Ermolenko, I.N. Zakharova, S.K. Zyryanov, E.V. Kasanave, et al.

    On March 19, 2026, in Moscow, an international interdisciplinary Expert Council convened during the III National Congress of Pediatric Neurologists to address the treatment of comorbid conditions associated with ADHD in children. It was observed that comorbid disorders, such as anxiety, sleep disturbances, and heightened nervous excitability, affect at least 70% of patients, exacerbating clinical symptoms of ADHD and diminishing treatment efficacy. The experts evaluated the evidence supporting the use of multicomponent low-dose formulations derived from plant extracts and minerals, specifically Nervoheel (for children aged 3 years and older) and Neurexan (for those aged 12 years and older). These formulations are approved in the Russian Federation as medical products and have demonstrated effectiveness in alleviating neurotic manifestations, anxiety, and sleep disorders, as well as improving focus and compliance. Following the Expert Council’s statement, these medications received a favorable evaluation regarding their effectiveness in managing anxiety, sleep disorders, and nervous. They were recommended for inclusion in the Ministry of Health of the Russian Federation’s clinical guidelines, with a strength of recommendation of C and a quality of evidence rating of 3.


  • Clinical experience with melatonin and memantine combination (Miladean) in children with cognitive and behavioral impairments

    by A.V. Goryunov, M.A. Morozova, A.A. Koval-Zaytsev, V.S. Britova, A.G. Beniashvili, O.V. Shushpanova, I.D. Gornushenkov, T.E. Blinova

    An open-label, single-arm pilot study evaluated the efficacy of the combined melatonin and memantine preparation (Miladean) as add-on therapy in 20 children and adolescents (aged 8—15 years) with cognitive and behavioral impairments within hyperkinetic conduct disorder (F90.1, n=7), schizotypal disorder (F21, n=10), and schizophrenia (F20, n=3). All patients received stable background therapy, to which Miladean was added (2 tablets sublingually at bedtime) for 8 weeks. Cognitive tests (Raven’s Progressive Matrices, Stroop test, computerized Go/No-Go task), sleep quality questionnaire (modified Spiegel scale), and ADHD symptom scales (SNAP-IV) were used to assess outcomes. The drug demonstrated a favorable safety and tolerability profile. A statistically significant reduction in symptoms of inattention and hyperactivity-impulsivity on the SNAP-IV scale (p<0.001), improved sleep quality (p=0.002), and increased reaction speed in the Go/No-Go task (p=0.001—0.033) were observed. A trend towards improved performance on the intelligence test (Raven’s Progressive Matrices, p=0.067—0.077) was noted. The preliminary data obtained at this study indicate the potential efficacy of Miladean in correcting cognitive and behavioral impairments in children across various diagnostic categories and justify conducting further double-blind, placebo-controlled studies.

  • Cogitum in the treatment of mental disorders in childhood

    by A.V. Goryunov, O.V. Shushpanova, T.E. Blinova, N.I. Golubeva

    The development of many mental disorders, including schizophrenia and autism, is associated with early organic damage to the central nervous system. Moreover, even in severe cases of schizophrenia and autism spectrum disorders, endogenous factors are the main cause of the disease, and organic lesions serve as triggers or aggravating circumstances. The drug Cogitum, a synthetic analog of N-acetylaspartate, is actively used in pediatric neuropsychiatry. This aspartic acid derivative, is critically important for brain development, hormonal regulation, and steroidogenesis. It is present in high concentrations in the brains of embryos and newborns, participating in key metabolic processes. The review analyzes current research on the use of Cognition in various mental disorders — ADHD, delayed speech development, asthenic conditions, autistic and schizophrenic spectrum disorders. According to the results of the studies presented in this article, the drug Cogitum has shown its effectiveness and safety for children. It is concluded that further studies of the therapeutic potential of Cogitum in various diseases are necessary to expand the indications for use.

  • Group Psychotherapy Focused on the Domain in the Emotional and Personality Domain in Adolescents with Schizophrenic Spectrum Disorders

    by V.S. Britova, A.A. Koval-Zaytsev, A.V. Goryunov, A.N. Barkhatova

    The narrative review describes modern ideas about the structural and dynamic features and disorders of the emotional and personal sphere in adolescents with schizophrenic spectrum disorders, and proves the therapeutic potential of group psychotherapy in the treatment of these disorders. The relevance of addressing emotional and personal deficits in adolescents is due to their impact on their social adjustment, the development of coping strategies, and the overall quality of life. The complexity of psychotherapy is due to a combination of immaturity and vulnerability of the emotional and personal sphere, specific to adolescents, combined with the actual age-related tasks of self-knowledge, implemented within the interpersonal interaction. The emotional and personal sphere of adolescents with schizophrenic spectrum disorders is characterized by a complex structure of disorders, including a decrease in the ability to perceive and express complex emotions, a deficit of mentalization and difficulties in interpreting social interactions, instability of self-esteem, hurtful experience of otherness, alienation from society and, as a result, fear of rejection, negative assessment, etc. These disorders, refracted through actual age-related tasks, are enhanced by social factors (isolation, stigmatization) and develop a specific pattern of social dysfunction, due to the close connection between clinical manifestations and normative phenomena of age-related development. Group psychotherapy is considered an effective method of complex treatment in various conditions and combinations of symptoms, due to the potent effect of nonspecific therapeutic mechanisms via processes of group dynamics and creating a supportive environment. The possibilities of various directions of group work are analyzed: psychoeducation, cognitive-behavioral approach, art therapy, and integrative methods. Promising directions for further research of group psychotherapy targeted for the emotional and personal sphere of adolescents with schizophrenic spectrum disorders are provided.

  • Aripiprazole in the treatment of psychiatric disorders in childhood

    by A.V. Goryunov, O.V. Shushpanova, T.E. Blinova

    For child psychiatry, the priority task is not only the relief of psychopathological symptoms, but also the preservation and restoration of cognitive functioning. Drugs that are active against a wide range of psychopathological disorders, including the productive, negative, affective, and cognitive domains, while having a favorable tolerance profile, will be the most suitable for solving this problem. The unique therapeutic profile of aripiprazole meets all these requirements. The efficacy and tolerability of Aripiprazole in children and adolescents have been demonstrated in many open-label clinical trials, which served as the basis for the drug’s approval by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia, bipolar disorder, and irritability associated with autistic disorder in children and adolescents. Aripiprazole is also included in national clinical guidelines for the treatment of autistic disorders. The high frequency of prescribing aripiprazole in childhood is due not only to its positive effect on negative, cognitive and affective symptoms, but also to its good general tolerance, low probability of developing extrapyramidal symptoms, absence of adverse effects on body weight and metabolic parameters (lipid profile, tissue sensitivity to insulin, etc.).